Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax combined with HAG for adult relapsed/refractory ETP-ALL
ChiCTR2100048966Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax, homoharringtonine, cytarabine and granulocyte colony-stimulating factor in early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Complete remission rate and Partial remission rate. Started Aug 2021; status: recruiting.
02
Drugs
venetoclaxhomoharringtoninecytarabinegranulocyte colony-stimulating factor
03
Conditions
early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)
Beyond the preview
Go deeper on ChiCTR2100048966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048966.